MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F51

Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease

Identifieur interne : 000F51 ( PascalFrancis/Corpus ); précédent : 000F50; suivant : 000F52

Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease

Auteurs : Greg T. Sutherland ; Gerhard A. Siebert ; Jeremy R. B. Newman ; Peter A. Silburn ; Richard S. Boyle ; John D. O'Sullivan ; George D. Mellick

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0136809

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Haplotype, Sporadique.

English descriptors

KwdEn :
- Haplotype, Nervous system diseases, Parkinson disease, Sporadic.

Abstract

Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease`
A11	`01`	`1`		`@1 SUTHERLAND (Greg T.)`
A11	`02`	`1`		`@1 SIEBERT (Gerhard A.)`
A11	`03`	`1`		`@1 NEWMAN (Jeremy R. B.)`
A11	`04`	`1`		`@1 SILBURN (Peter A.)`
A11	`05`	`1`		`@1 BOYLE (Richard S.)`
A11	`06`	`1`		`@1 O'SULLIVAN (John D.)`
A11	`07`	`1`		`@1 MELLICK (George D.)`
A14	`01`			`@1 Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University @2 Brisbane, Queensland @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 7 aut.`
A14	`02`			`@1 UQ Centre for Clinical Research, School of Medicine, University of Queensland @2 Brisbane, Queensland @3 AUS @Z 4 aut.`
A14	`03`			`@1 Department of Neurology, Princess Alexandra Hospital @2 Brisbane, Queensland @3 AUS @Z 5 aut. @Z 7 aut.`
A14	`04`			`@1 Department of Neurology, Royal Brisbane and Women's Hospital @2 Brisbane, Queensland @3 AUS @Z 6 aut. @Z 7 aut.`
A20				`@1 449-452`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186999840220`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 09-0136809`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Haplotype @5 09`
C03	`03`	`X`	`ENG`	`@0 Haplotype @5 09`
C03	`03`	`X`	`SPA`	`@0 Haplotipo @5 09`
C03	`04`	`X`	`FRE`	`@0 Sporadique @5 10`
C03	`04`	`X`	`ENG`	`@0 Sporadic @5 10`
C03	`04`	`X`	`SPA`	`@0 Esporádico @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 096`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0136809 INIST
ET :	Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease
AU :	SUTHERLAND (Greg T.); SIEBERT (Gerhard A.); NEWMAN (Jeremy R. B.); SILBURN (Peter A.); BOYLE (Richard S.); O'SULLIVAN (John D.); MELLICK (George D.)
AF :	Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University/Brisbane, Queensland/Australie (1 aut., 2 aut., 3 aut., 4 aut., 7 aut.); UQ Centre for Clinical Research, School of Medicine, University of Queensland/Brisbane, Queensland/Australie (4 aut.); Department of Neurology, Princess Alexandra Hospital/Brisbane, Queensland/Australie (5 aut., 7 aut.); Department of Neurology, Royal Brisbane and Women's Hospital/Brisbane, Queensland/Australie (6 aut., 7 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 449-452; Bibl. 21 ref.
LA :	Anglais
EA :	Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Haplotype; Sporadique
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Haplotype; Sporadic
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Haplotipo; Esporádico
LO :	INIST-20953.354000186999840220
ID :	09-0136809

Links to Exploration step

Pascal:09-0136809

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease</title>
<author><name sortKey="Sutherland, Greg T" sort="Sutherland, Greg T" uniqKey="Sutherland G" first="Greg T." last="Sutherland">Greg T. Sutherland</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siebert, Gerhard A" sort="Siebert, Gerhard A" uniqKey="Siebert G" first="Gerhard A." last="Siebert">Gerhard A. Siebert</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Newman, Jeremy R B" sort="Newman, Jeremy R B" uniqKey="Newman J" first="Jeremy R. B." last="Newman">Jeremy R. B. Newman</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Silburn, Peter A" sort="Silburn, Peter A" uniqKey="Silburn P" first="Peter A." last="Silburn">Peter A. Silburn</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>UQ Centre for Clinical Research, School of Medicine, University of Queensland</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boyle, Richard S" sort="Boyle, Richard S" uniqKey="Boyle R" first="Richard S." last="Boyle">Richard S. Boyle</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Royal Brisbane and Women's Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mellick, George D" sort="Mellick, George D" uniqKey="Mellick G" first="George D." last="Mellick">George D. Mellick</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Royal Brisbane and Women's Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0136809</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0136809 INIST</idno>
<idno type="RBID">Pascal:09-0136809</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F51</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease</title>
<author><name sortKey="Sutherland, Greg T" sort="Sutherland, Greg T" uniqKey="Sutherland G" first="Greg T." last="Sutherland">Greg T. Sutherland</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siebert, Gerhard A" sort="Siebert, Gerhard A" uniqKey="Siebert G" first="Gerhard A." last="Siebert">Gerhard A. Siebert</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Newman, Jeremy R B" sort="Newman, Jeremy R B" uniqKey="Newman J" first="Jeremy R. B." last="Newman">Jeremy R. B. Newman</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Silburn, Peter A" sort="Silburn, Peter A" uniqKey="Silburn P" first="Peter A." last="Silburn">Peter A. Silburn</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>UQ Centre for Clinical Research, School of Medicine, University of Queensland</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boyle, Richard S" sort="Boyle, Richard S" uniqKey="Boyle R" first="Richard S." last="Boyle">Richard S. Boyle</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Royal Brisbane and Women's Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mellick, George D" sort="Mellick, George D" uniqKey="Mellick G" first="George D." last="Mellick">George D. Mellick</name>
<affiliation><inist:fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Royal Brisbane and Women's Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Haplotype</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Sporadic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Haplotype</term>
<term>Sporadique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SUTHERLAND (Greg T.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SIEBERT (Gerhard A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NEWMAN (Jeremy R. B.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SILBURN (Peter A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BOYLE (Richard S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>O'SULLIVAN (John D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MELLICK (George D.)</s1>
</fA11>
<fA14 i1="01"><s1>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>UQ Centre for Clinical Research, School of Medicine, University of Queensland</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Royal Brisbane and Women's Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>449-452</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186999840220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0136809</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Haplotype</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Haplotype</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Haplotipo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sporadique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sporadic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Esporádico</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>096</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0136809 INIST</NO>
<ET>Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease</ET>
<AU>SUTHERLAND (Greg T.); SIEBERT (Gerhard A.); NEWMAN (Jeremy R. B.); SILBURN (Peter A.); BOYLE (Richard S.); O'SULLIVAN (John D.); MELLICK (George D.)</AU>
<AF>Eskitis Institute for Cell and Molecular Therapies, School of Biomolecular and Physical Sciences, Griffith University/Brisbane, Queensland/Australie (1 aut., 2 aut., 3 aut., 4 aut., 7 aut.); UQ Centre for Clinical Research, School of Medicine, University of Queensland/Brisbane, Queensland/Australie (4 aut.); Department of Neurology, Princess Alexandra Hospital/Brisbane, Queensland/Australie (5 aut., 7 aut.); Department of Neurology, Royal Brisbane and Women's Hospital/Brisbane, Queensland/Australie (6 aut., 7 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 449-452; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Familial Parkinsonism (PARK) genes are strong candidates for conferring susceptibility to common forms of PD. However, most studies to date have provided little evidence that their common variants substantially influence disease risk. Recently, mutations were described in the gene, GIGYF2 (TNRC15), located at the PARK11 locus (2q37.1). Here, we use a haplotype tagging approach to examine common variation in the GIGYF2 gene and PD risk. PD cases (n = 568) and age and gender-matched control subjects (n = 568) were recruited from three specialist movement disorder clinics in Brisbane (Australia) and the Australian electoral roll. Twelve tagging SNPs were assessed in all subjects and haplotype and genotype associations were explored. Overall our findings suggest that common genetic variants of GIGYF2 do not significantly affect sporadic PD risk in Australian Caucasians.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Haplotype; Sporadique</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Haplotype; Sporadic</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Haplotipo; Esporádico</SD>
<LO>INIST-20953.354000186999840220</LO>
<ID>09-0136809</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F51 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F51 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0136809
   |texte=   Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease

Haplotype Analysis of the PARK 11 Gene, GIGYF2, in Sporadic Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri